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Abstract
Background: Atrial septal defect (ASD) accounts for 10% of all congenital heart lesions and
represent the third most congenital cardiac defect seen in adults. Atrial natriuretic peptide (ANP)
is an important regulator of the sodium and volume homeostasis. This study was designed to
investigate the changes in plasma ANP concentrations and three-dimensional echocardiography
(3DE) measurements of cardiac volume in patients with ASD during transcatheter closure of
defect.
Methods: Plasma ANP concentrations and transthoracic 3DE measurements of right ventricular
volume were performed in 46 patients with ASD before closure, and at 3 days after closure. 22
healthy subjects matched for age, sex served as control subjects.
Results: The 46 patients (20 men, 26 women; mean age 26.32 ± 13.28, range 6 to 63 years) were
diagnosed to secundum ASD (the stretched diameters of ASD were from 9~36(25.34 ± 7.80 mm),
and had been successfully placed Amplatzer septal occluder (the sizes of occluder were from 11 to
40 mm). The results showed that compared with control subjects, plasma ANP concentrations
were elevated in patients with ASD. Plasma ANP concentrations positively correlated significantly
with pulmonary artery pressure (PAP) (r = 0.74, p < 0.05) and 3DE measurements of cardiac
volumes (right ventricular end-diastolic (r = 0.50, p < 0.05) and end-systolic volume (r = 0.50, p <
0.05) and negatively correlated with RVEF (r = -0.38, p < 0.05). Transthoracic 3DE measurements
of right ventricular volume and plasma ANP concentrations decreased significantly at 3 days after
closure (p < 0.05) compared with it before closure.
Conclusion: Plasma ANP concentrations were markedly elevated in patients with pulmonary
arterial hypertension and right ventricular volume overload and decreased significantly after
closure of ASD. This study suggested that ANP may help to identify patients with ASD complicated
by pulmonary arterial hypertension and right ventricular volume overload that demanded early
intervention and may become effective marker for evaluating changes in cardiac load after
transcatheter ASD closure.
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Background
Atrial septal defect (ASD) accounts for 10% of all congen-
ital heart lesions and represent the third most congenital
cardiac defect seen in adults[1]. This lesion is sometimes
associated with the development of pulmonary arterial
hypertension (PAH), right ventricular volume overload,
congestive heart failure and atrial arrhythmias [1].
Surgical closure of the defect aims at relieving the heart
and pulmonary circulation from the haemodynamic bur-
den. Although patients benefit from surgical occlusion of
the defect, they still have cardiovascular morbidity after
the operation [1]. A new technique using the Amplatzer
septal occluder was developed for the transcatheter clo-
sure of ASD [1-4]. This device is simple in construction,
easy to deploy, and can be withdrawn and repositioned
many times. It carries the advantages of fewer complica-
tions, avoidance of cardioplegia and cardiopulmonary
bypass, shorter hospitalization, reduced need for blood
products, and less patient discomfort. Although satisfac-
tory results have been reported with transcatheter closure
of ASD, there are some complications in this procedure.
The type and rate of complications are different among
different devices. Chessa et al [4] reported the emboliza-
tion/malposition was the most common complication.
Arrhythmias were the next most common complications.
The other complications included right iliac vein dissec-
tion; groin hematoma, retropharynx hemorrhage.
ANP, a cardiac neurohormone secreted in the right atrium
in response to increased right atrial pressure as well as vol-
ume loads [5,6]. It is an important regulator of the
sodium and volume homeostasis[7]. It may be elevated in
patients with congenital and acquired heart disease [8].
The present study was designed to evaluate the correlation
between plasma ANP concentrations and PAP and right
ventricular volume overload, and to investigate the
changes in plasma ANP concentrations in patients with
ASD during transcatheter closure of defects.
Methods
Study subjects
46 secundum ASD patients (20 men, 26 women; mean
age 26.32 ± 13.28, range 6 to 63 years) and 22 healthy vol-
unteers matched for sex and age (12 men, 10 women;
mean age 24.81 ± 9.04, range 16 to 43 years) who served
as control subjects were included in the study. We diag-
nosed all ASD patients by echocardiography. This study
protocol was approved by the institutional ethics commit-
tee for human subjects. Informed consent was obtained
for each study subject prior to participation in the study.
Blood sampling and assay for ANP [9]
Blood samples were drawn from peripheral vein before
and 3 days after transcatheter closure. Blood was immedi-
ately transferred into chilled glass tubes containing 2%
disodium ethylenediamine tetraacetic acid (1 mg ml-1)
and aprotinin (500 U ml-1) and centrifuged immediately
at 3000 rpm for 10 min at 4°C. The collected plasma sam-
ples were then stored at -70°C until final analysis. Plasma
ANP concentrations were measured directly with specific
immunoradiometric assay kits (RIA ANP assay kit, Radio-
immunoassay Center, General Hospital of Chinese PLA,
Beijing, P.R. China).
Three-dimensional echocardiographic image acquisition 
and volume calculation [10,11]
Transthoracic echocardiographic examination was under-
taken with the patient lying supine or in the left lateral
semi-recumbent position. Sedation was not used. Images
were obtained with commercially available ultrasound
equipment (SONOS 5500 and 7500, Hewlett-Packard
Company, Andover, Mass) and saved in digital form on
the hard disk of the ultrasound scanner. Standard par-
asternal, apical, and subcostal views were used. 3DE was
done using rotational image acquisition from the apical
view for right ventricle, with ECG and respiratory gating
(Fig 1). 3DE images were reconstructed by Tom-Tec Echo-
View 4.2 (TomTec Imaging Systems GmHb, Munich, Ger-
many). The right ventricular end-diastolic volume
(RVEDV) and end-systolic volume (RVESV) were meas-
ured from each 3DE data set with "summation of disks"
method, and stroke volume and ejection fraction (EF) was
derived from those (Fig 2).
Transcatheter closure of atrial septal defect [2]
Briefly, implantation of the Amplatzer device was per-
formed under general or local anesthesia with the guid-
ance of transoesophageal or transthoracic
echocardiography and fluoroscopy. First, a standard right
heart catheterization was performed. Baseline hemody-
namic variables including PAP, mean right atrial pressure
and right ventricular end-diastolic pressure were meas-
ured in all patients. The stretched diameters of the ASD
were measured by balloon sizing. The device for closing
the ASD was selected to match the stretched diameter or
1~2 mm larger. After balloon sizing, the introducing
sheath was inserted into the left atrium. Under fluoro-
scopic control, the delivery system, already loaded with
the device, was introduced into the left atrium through the
introducing sheath. After the waist and distal disc were
deployed in the middle left atrium, the delivery system
was gently pulled back against the atrial septum. Only
when the waist was correctly positioned in the ASD, was
the right atrial disc (proximal disc) deployed in the right
atrium by slowly retracting the introducing sheath while
keeping gentle traction on the cable. After the proper posi-Cardiovascular Ultrasound 2008, 6:35 http://www.cardiovascularultrasound.com/content/6/1/35
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tion was verified by transoesophageal or transthoracic
echocardiography and fluoroscopy, the device was
released (Fig 3). Aspirin treatment (3~5 mg/kg) was
started 24 hours before transcatheter closure and contin-
ued for six months.
Statistics
The results are expressed as mean ± standard deviation.
Two-tailed, unpaired Student's t tests were used for com-
parison of variables between two groups. The multiple
linear stepwise regression analysis was used to evaluate
the associations between ANP and PAP, 3DE measure-
ments. Treatment effects of transcatheter closure of defect
were analyzed with the Student t test for paired samples.
P-values < 0.05 were considered statistically significant.
The statistical analyses were done using SPSS statistical
software (SPSS for Windows, version 10.0, 1999, SPSS
Inc, Chicago, IL).
Results
Transcatheter closure of ASD and three-dimensional
echocardiographic examinations were successfully per-
formed in all patients, achieving a complete occlusion 3
days postoperatively in 100% of patients, and there were
no complications, such as arrhythmia, embolization, or
cardiac tamponade after the procedure. All patients had a
single device implanted. The sizes of occluder were from
11 to 40 mm. The acquisition time of the echocardio-
graphic data ranged from 8 to 10 minutes. Off-line image
processing and analysis required on average 45 minutes.
Clinical characteristics of patients with ASD and control 
subjects
The Clinical characteristics of patients with ASD and con-
trol subjects were listed in Table 1. There were no signifi-
cant differences between the two groups with regard to
age, sex.
Graph of 3DE acquisition in a patient with ASD after transcatheter closure Figure 1
Graph of 3DE acquisition in a patient with ASD after transcatheter closure.Cardiovascular Ultrasound 2008, 6:35 http://www.cardiovascularultrasound.com/content/6/1/35
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Plasma ANP concentrations and 3DE measurements
Plasma ANP concentrations and 3DE measurements of
cardiac volume were shown in Table 1. Compared with it
in control subjects, plasma ANP concentrations before
closure were significantly elevated. The RVEDV and
RVESV were enlarged in patients with ASD compared with
those in control subjects, resulting in a marked decrease of
the RVEF from control subjects.
Correlation between Plasma ANP concentrations with PAP
PAP was 38.54 ± 11.02 mmHg among the 46 patients
with ASD in whom this was measured during transcathe-
ter closure of defects. There were significant positive corre-
lation between plasma ANP concentrations and PAP (r =
0.74; p < 0.05) (Fig 4).







Age(years) 26.32 ± 13.28 24.81 ± 9.04 NS
Sex(M/F) 20/26 12/10 NS
ASD (TEE) (mm) 27.42 ± 5.92
ASD (balloon) (mm) 25.34 ± 7.80
PAP(mmHg) 36.48 ± 10.30
RVEDV(ml) 106.54 ± 25.97 69.78 ± 10.46 <0.05
RVESV(ml) 59.73 ± 17.59 33.84 ± 7.18 <0.05
RVEF(%) 44.10 ± 4.72 51.92 ± 5.35 <0.05
ANP(ng/L) 156.42 ± 75.10 82.85 ± 17.80 <0.05
Data are presented mean value ± SD or number (%). ASD = atrial 
septal defect; TEE = transesophageal echocardiography; RVEDV = 
right ventricular end-diastolic volume; RVESV = right ventricular end-
systolic volume; RVEF = right ventricular ejection fraction; ANP = 
atrial natriuretic peptide
General views of 3DE reconstruction of the RV and measurement of RV volume and RVEF in a patient with ASD Figure 2
General views of 3DE reconstruction of the RV and measurement of RV volume and RVEF in a patient with ASD [Diastolic 
phase (left), Systolic phase (right)].
Transesophageal echocardiographic image of transcatheter  ASD closure Figure 3
Transesophageal echocardiographic image of transcatheter 
ASD closure.Cardiovascular Ultrasound 2008, 6:35 http://www.cardiovascularultrasound.com/content/6/1/35
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Correlation between Plasma ANP concentrations and 3DE 
measurements
Before closure, in 46 patients with ASD, the plasma ANP
concentrations positively correlated with RVEDV (r = 050;
p < 0.05) and RVESV (r = 050; p < 0.05); and it negatively
correlated with RVEF (r = -0.38; p < 0.05) (Fig 5).
Effect of transcatheter closure of ASD on plasma ANP 
concentrations and 3DE measurements
46 patients with ASD underwent transcatheter closure of
ASD, plasma ANP concentrations and 3DE measurements
were measured before and 3 days after transcatheter clo-
sure of ASD with the Amplatzer septal occluder. Fig 6, Fig
7 and Fig 8 showed the changes of plasma ANP concentra-
tions, right ventricular volume and ejection fraction after
transcatheter closure of ASD. After closure, the plasma
ANP concentrations decreased from 156.42 ± 75.10 ng/L
to 101.78 ± 35.72 ng/L (p < 0.05), the RVEDV, RVESV
decreased (P < 0.05), and the RVEF (P < 0.05) increased.
Discussion
Previous studies evaluated the RV geometric change
response to transcatheter closure of ASD by the measure-
ment of a single RV dimension in a long- or short-axis
view, or both [3,12,13]. RV dimension does not ade-
quately reflect the complex geometry of the right ventricle,
and there are no clear landmarks to ensure that this
dimension is measured in the same anatomic location
across serial studies. We used a three-dimensional
echocardiographic volumetry to calculate RV volumes.
This model might offer even more accurate assessment of
right-sided chamber volumes. Thus, the measurement of
RV volumes in this study allowed much more confidence
than the measurement of a simple linear dimension.
In this study, we showed that (1) plasma ANP concentra-
tions were elevated in patients with ASD regardless of the
presence of PAH, (2) plasma ANP concentrations were
correlated positively with PAP, RVEDV and RVESV; and
correlated negatively with RVEF, and (3) after transcathe-
ter closure of ASD, plasma ANP concentrations were
markedly decreased, the RVEDV, RVESV decreased and the
RVEF increased markedly.
These findings are consistent with previous reports on
ANP that showed a positive correlation between plasma
ANP concentrations and Qp/Qs and a positive correlation
between plasma ANP and PAP in patients with different
types of congenital heart disease, including ASD
[5,14,15].
Correlation between plasma ANP concentrations with EVEDV (A), RVEF (B) Figure 5
Correlation between plasma ANP concentrations with EVEDV (A), RVEF (B).
Correlation between plasma ANP concentrations with PAP Figure 4
Correlation between plasma ANP concentrations with PAP.Cardiovascular Ultrasound 2008, 6:35 http://www.cardiovascularultrasound.com/content/6/1/35
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ANP is a 28 amino acid peptide and produced primarily
in the cardiac atria [8], stimulated by atrial stretch, for
example, volume overloading. ANP is a biologically active
peptide with natriuretic and diuretic activities. In our
study, plasma ANP concentrations were correlated posi-
tively with PAP and RVEDV in patients with ASD. These
results imply that ANP may be released in response to
right heart volume overload caused by the left-to right
shunt in patients with ASD. Possible pathophysiologic
significance of ANP increase in patients with ASD may
relate to their pulmonary vasodilative effect. Increased
ANP concentrations in patients with ASD correlated posi-
tively with PAP may play an important role in protecting
the pulmonary bed.
In the last 50 years cardiac catheterization has changed its
primary role from a diagnostic to that of a therapeutic pro-
cedure. Most recently, ASD transcatheter occlusion tech-
niques have become an alternative to surgical procedure
using cardiopulmonary bypass [4]. Our study showed that
the plasma ANP concentrations decreased markedly at 3
days after transcatheter closure and there was a significant
decrease in right ventricular volume by 3 days after tran-
scatheter closure. Muta et al [16] demonstrated that the
plasma ANP concentrations at 1 month after ASD closure
decreased and were similar to control values. Schussler et
al [17] demonstrated right ventricular volumes decreased
by 22%, 30%, and 41% at 1 day, 1 month, and 6 months,
respectively, after successful transcatheter closure of large
ASDs. Right atrial areas decreased by 5%, 23%, and 26%,
respectively, over the same time. Presumably, the early
reduction in right heart size is secondary to removal of the
left-to-right shunt and reduction of pro-load [3]. Right
ventricular volumes continued to improve for up to 6
months, suggesting an ongoing remodeling process [17].
The mechanism of ANP decreases may reflect a reduction
of volume overload of right heart.
Although it became readily apparent that 3DE provides
more accurate and reliable measurements of right ven-
tricular volume and function, the complex image acquisi-
tion and off-line data processing have limited the use of
3DE in daily clinical practice.
Conclusion
The ASD was found to be associated with increased right
ventricular volume, pulmonary arterial hypertension and
was accompanied by increased plasma ANP concentra-
tions, probably due to long-standing atrial stretch, when
compared with controls. The change in plasma ANP con-
centrations may reflect changes in cardiac load during
transcatheter closure of ASD. Thus plasma ANP concen-
trations can reflect pressure and volume loads to the pul-
monary artery and right ventricle, and may be helpful in
identifying patients with ASD and pulmonary arterial
hypertension that demands early intervention.
Bar graph showed RVEF in patients with ASD before and  after closure Figure 8
Bar graph showed RVEF in patients with ASD before and 
after closure. *p < 0.05.
Bar graph showed plasma ANP concentrations in patients  with ASD before and after closure Figure 6
Bar graph showed plasma ANP concentrations in patients 
with ASD before and after closure. *p < 0.05.
Bar graph showed RVEDV and RVESV in patients with ASD  before and after closure Figure 7
Bar graph showed RVEDV and RVESV in patients with ASD 
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